

Advancing Translational Science for Pulmonary Nontuberculous Infections. A Road Map for Research

American Journal of Respiratory and Critical Care Medicine
199, 947-951

DOI: [10.1164/rccm.201807-1273pp](https://doi.org/10.1164/rccm.201807-1273pp)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Editorial: NTMâ€™The New Uber-Bugs. <i>Frontiers in Microbiology</i> , 2019, 10, 1299.	1.5	7
2	Repositioning rifamycins for <i>Mycobacterium abscessus</i> lung disease. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 867-878.	2.5	49
3	Recent advances in nontuberculous mycobacterial lung infections. <i>F1000Research</i> , 2019, 8, 1710.	0.8	18
4	<i>Mycobacterium abscessus</i> , an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5868.	1.8	84
5	Prevention of transmission of <i>Mycobacterium abscessus</i> among patients with cystic fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 646-653.	1.2	18
6	Pulmonary non-tuberculous mycobacterial infections: current state and future management. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 799-826.	1.3	41
7	Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000591.	1.2	14
8	Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of <i>Mycobacterium abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	33
9	Rifabutin: A Repurposing Candidate for <i>Mycobacterium abscessus</i> Lung Disease. <i>Frontiers in Microbiology</i> , 2020, 11, 371.	1.5	7
10	Extreme Drug Tolerance of <i>Mycobacterium abscessus</i> â€™Persistsâ€™. <i>Frontiers in Microbiology</i> , 2020, 11, 359.	1.5	42
11	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	3.1	336
12	miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. <i>Scientific Reports</i> , 2020, 10, 3178.	1.6	19
13	The Many Hosts of <i>Mycobacteria 8 (MHM8)</i> : A conference report. <i>Tuberculosis</i> , 2020, 121, 101914.	0.8	6
14	Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 1127-1137.	2.9	23
15	Is It Time to Move the Goalposts?. <i>Clinical Infectious Diseases</i> , 2021, 72, 1138-1140.	2.9	1
16	One Step Closer: Nontuberculous Mycobacterial Pulmonary Disease and Predicted Mortalityâ€™The BACES Score. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 163-164.	2.5	1
17	Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care. <i>International Journal of Infectious Diseases</i> , 2021, 113, S73-S77.	1.5	9
18	<i>Mycobacterium abscessus</i> biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections. <i>Scientific Reports</i> , 2021, 11, 5020.	1.6	16

#	ARTICLE	IF	CITATIONS
19	A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Antimycobacterial Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	23
20	Subunit vaccine protects against a clinical isolate of <i>Mycobacterium avium</i> in wild type and immunocompromised mouse models. <i>Scientific Reports</i> , 2021, 11, 9040.	1.6	15
22	Rifampicinâ€“Liposomes for <i>Mycobacterium abscessus</i> Infection Treatment: Intracellular Uptake and Antibacterial Activity Evaluation. <i>Pharmaceutics</i> , 2021, 13, 1070.	2.0	13
23	Piperidine-4-Carboxamides Target DNA Gyrase in <i>Mycobacterium abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0067621.	1.4	14
25	MicroRNA-155 Modulates Macrophagesâ€™ Response to Non-Tuberculous Mycobacteria through COX-2/PGE2 Signaling. <i>Pathogens</i> , 2021, 10, 920.	1.2	6
26	A <i>Mycobacterium tuberculosis</i> NBTI DNA Gyrase Inhibitor Is Active against <i>Mycobacterium abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0151421.	1.4	10
27	Whole Genome Sequencing in the Management of Non-Tuberculous Mycobacterial Infections. <i>Microorganisms</i> , 2021, 9, 2237.	1.6	15
28	The Role of Biofilms, Bacterial Phenotypes, and Innate Immune Response in <i>Mycobacterium avium</i> Colonization to Infection. <i>Journal of Theoretical Biology</i> , 2022, 534, 110949.	0.8	7
29	Cyclohexyl-griselimycin Is Active against <i>Mycobacterium abscessus</i> in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0140021.	1.4	8
31	Environment in the lung of cystic fibrosis patients stimulates the expression of biofilm phenotype in <i>Mycobacterium abscessus</i> . <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	2
32	Sex, ancestry, senescence, and aging (SAnSA) are stark drivers of nontuberculous mycobacterial pulmonary disease. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2022, 26, 100297.	0.6	3
33	Antimicrobial Activity of Neutrophils Against Mycobacteria. <i>Frontiers in Immunology</i> , 2021, 12, 782495.	2.2	15
35	Novel Screening System of Virulent Strains for the Establishment of a <i>Mycobacterium avium</i> Complex Lung Disease Mouse Model Using Whole-Genome Sequencing. <i>Microbiology Spectrum</i> , 2022, 10, e0045122.	1.2	4
38	Strongly Bactericidal All-Oral β -Lactam Combinations for the Treatment of <i>Mycobacterium abscessus</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	10
39	Why Matter Matters: Fast-Tracking <i>Mycobacterium abscessus</i> Drug Discovery. <i>Molecules</i> , 2022, 27, 6948.	1.7	7
40	<i>Mycobacterium tuberculosis</i> DprE1 Inhibitor OPC-167832 Is Active against <i>Mycobacterium abscessus</i> <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	7
41	Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3. <i>Tuberculosis</i> , 2023, 138, 102288.	0.8	4
42	Omadacycline for management of <i>Mycobacterium abscessus</i> infections: a review of its effectiveness, place in therapy, and considerations for use. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	1

#	ARTICLE	IF	CITATIONS
43	Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen. Tuberculosis, 2023, 138, 102302.	0.8	4
44	Environmental risk of nontuberculous mycobacterial infection: Strategies for advancing methodology. Tuberculosis, 2023, 139, 102305.	0.8	6
45	Mycobacterium abscessus infection results in decrease of oxidative metabolism of lung airways cells and relaxation of the epithelial mucosal tight junctions. Tuberculosis, 2023, 138, 102303.	0.8	0
46	A novel chemogenomic discovery platform identifies bioactive hits with rapid bactericidal activity against Mycobacteroides Abscessus. Tuberculosis, 2023, 139, 102317.	0.8	0
47	Repurposing β -Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study. Antibiotics, 2023, 12, 335.	1.5	0